# Bionomics Announced The Outcomes Of An End-of-phase 2 Meeting With The FDA For BNC210 For The Acute Treatment Of Social Anxiety Disorder Into Phase 3 ...
**FDA Update**

**2023-10-16 11:10**

**https://www.ainvest.com/news/bionomics-announced-outcomes-of-an-end-of-phase-2-meeting-with-fda-for-bnc210-for-acute-treatment-of-social-anxiety-disorder-into-phase-3-studies-2310100064fcab08e65697ad/**

Bionomics Announced The Outcomes Of An End-of-phase 2 Meeting With The FDA For BNC210 For The Acute Treatment Of Social Anxiety Disorder Into Phase 3 Studies